share_log

迈威生物自愿披露关于9MW2821联合特瑞普利单抗一线治疗尿路上皮癌纳入突破性治疗品种公示名单的公告

Maiwei Biotech voluntarily disclosed an announcement on the inclusion of 9MW2821 and treprilizumab in the first-line treatment of urothelial cancer in the public list of breakthrough treatment varieties

SZSI ·  Jan 9
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more